The ITP World Impact Survey (I-WISh) is a collaborative investigation among global ITP experts, patient support groups and Novartis Pharmaceuticals Corporation. The purpose of this cross-sectional global survey is to analyze and report the real-world impact of immune thrombocytopenia (ITP) on patients’ quality of life, management of the condition, and opinions toward treatment. I-WISh is the largest observational global survey ever conducted in ITP including 1,400 ITP patients and 480 health care providers who treat the condition from the following 14 countries: Canada, China, Colombia, Egypt, France, Germany, Italy, India, Japan, Norway, Spain, Turkey, United Kingdom, and United States.




Steering Committee

Members of the I-WISh international steering committee of clinical experts and patient advocates:

  • Donald M. Arnold, MDCM; McMaster University (Canada)
  • James Bussel, MD; Weill Cornell Medical College (US)
  • Nichola Cooper, MD; Hammersmith Hospital, Imperial College London (UK)
  • Waleed Ghanima, MD, PhD; Ostfold Hospital (Norway)
  • Ming Hou, MD, PhD; Shandong University (China)
  • Alexandra Kruse; Platelet Disorder Support Association (US)
  • Caroline Kruse; Platelet Disorder Support Association (US)
  • Serge Laborde; O’Ctyo (France)
  • Barbara Lovrencic; Italian Association Immune Thrombocytopenia (Italy)
  • Axel Matzdorff, MD; Caritasclinic Saarbruecken (Germany)
  • Mervyn Morgan; ITP Support Association (UK)
  • Marc Michel, MD; Henri Mondor University Hospital, Université Paris-Est Créteil (France)
  • Drew Provan, MD; BMI, The London Independent Hospital (UK)
  • Cristina Santoro, MD; Sapienza University of Rome (Italy)
  • Yoshiaki Tomiyama, MD; Osaka University Hospital (Japan)
  • Shirley Watson; ITP Support Association (UK)

About Immune Thrombocytopenia (ITP)

Immune thrombocytopenia (THROM-bo-si-to-PE-ne-ah) or ITP is a rare autoimmune condition that can be as challenging to pronounce as it is to live with. Characterized by low blood platelet counts, you may hear ITP called by its original name of idiopathic thrombocytopenic purpura. Historically, “idiopathic” was used because the cause of the condition was unknown. Today it is known that ITP is caused by the body’s immune system destroying healthy platelets which leads to easy or excessive bruising and bleeding, debilitating fatigue as well as a roller coaster of emotions and ongoing medical management.


Sponsored by Novartis Pharmaceutical Corporation